A Phase II study of autologous mesenchymal stromal cells and c‐kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT‐HF trial

Citations Over TimeTop 1% of 2021 papers

Abstract

This is the first multicentre trial assessing CPCs and a combination of two cell types from different tissues in HF patients. The results show that treatment is safe and feasible. Even with maximal guideline-directed therapy, both CPCs and MSCs were associated with improved clinical outcomes (MACE and quality of life, respectively) in ischaemic HF without affecting left ventricular function or structure, suggesting possible systemic or paracrine cellular mechanisms. Combining MSCs with CPCs was associated with improvement in both these outcomes. These results suggest potential important beneficial effects of CPCs and MSCs and support further investigation in HF patients.

Related Papers

• The Expression of SCL Gene in Bone Marrow Stromal Cells From Patients with Leukemia and Normal Individuals(2002)
• Study on Bone Marrow-derived Stromal Cells Enhancement of Hematopoiesis Reconstitution(2004)
• Observation on the biological behavior of acute leukemia bone marrow stroma cells(2005)
• Experimental study on the levels of IL-1α、IL-1β and IL-11 secreted by bone marrow stromal cells of patients with psoriasis(2009)
• Study of The Level of TNF-α,LIF and HGF Secreted by Bone Marrow Stromal Cells in Psoriatic Patients(2009)